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Abstract
To reduce the risks associated with live-attenuated immunodeficiency virus vaccines, single-cycle immunodeficiency viruses (SCIVs)
were developed by primer complementation and production of the vaccine in the absence of vif in a vif-independent cell line. After a single
intravenous injection of SCIVs into rhesus monkeys, peak viral RNA levels of 103 to 104 copies/ml plasma were observed, indicating
efficient expression of SCIV in the vaccinee. After booster immunizations with SCIVs, SIV-specific humoral and cellular immune responses
were observed. Although the vaccine doses used in this pilot study could not protect vaccinees from subsequent intravenous challenge with
pathogenic SIVmac239, our results demonstrate that the novel SCIV approach allows us to uncouple in vivo expression levels from the viral
replicative capacity facilitating the analysis of the relationship between viral expression levels or viral genes and immune responses induced
by SIV.
© 2003 Elsevier Science (USA). All rights reserved.
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Introduction
Live-attenuated immunodeficiency viruses such as nef
deletion mutants of SIV were shown to be effective vac-
cines which protect from the development of AIDS in the
SIV-macaque model (reviewed in Desrosiers, 1996; John-
son, 1999). They induce protection against pathogenic ho-
mologous and heterologous viruses after intravenous or
mucosal challenge as demonstrated in a number of studies
(Almond et al., 1995; Bogers et al., 1995; Clements et al.,
1995; Daniel et al., 1992; Dunn et al., 1997; Gundlach et al.,
1998; Johnson et al., 1999; Marthas et al., 1990; Miller et
al., 1997; Norley et al., 1996; Putkonen et al., 1995; Que-
sada-Rolander et al., 1996; Shibata et al., 1997; Stahl-
Hennig et al., 1996; Wyand et al., 1996, 1999). However,
safety still is the predominant concern for the use of live-
attenuated immunodeficiency viruses in humans. During
primary infection nef deletion mutants of SIV replicate to
substantial titers (Kestler et al., 1991) and some infected
monkeys develop AIDS at later time points (Baba et al.,
1999). Progression to AIDS after infection with nef deletion
mutants is also observed in newborn monkeys (Baba et al.,
1995; Wyand et al., 1997). Further attenuation of live-
attenuated immunodeficiency virus vaccines seems to be
limited due to loss of vaccine efficacy which declines with
decreasing replicative capacity of the vaccine virus (John-
son et al., 1999; Lohman et al., 1994).
The cellular or molecular mechanisms mediating protec-
tion after immunization with live-attenuated immunodefi-
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ciency virus vaccines remain unknown. It is also unclear
why other vaccine approaches which show good immuno-
genicity are less effective in inducing protection against
AIDS. Characteristic properties of effective live-attenuated
immunodeficiency virus vaccinees are the production of
viral particles by the vaccines in large amounts over weeks
to months. Therefore, the goal of the present study was to
closely mimic the live-attenuated immunodeficiency viruses
with respect to these properties by using an immunodefi-
ciency virus, which can undergo only a single round of
replication. These single-cycle immunodeficiency viruses
(SCIVs) aim to maintain the immunostimulatory capacity of
live-attenuated immunodeficiency viruses but lack their
pathogenic potential. After injection of the vaccine in the
host the SCIVs should integrate into the genome of the
infected host cells and persist for the lifetime of the infected
host cells. The infected host cells should express all struc-
tural genes of immunodeficiency viruses leading to the
production of viral particles which have the same structural
protein composition as wild-type viruses. The viral Env
protein should be fusion competent, which might also favor
the production of neutralizing antibodies (LaCasse et al.,
1999). However, the particles generated by the infected host
cells should be not infectious. Expression of the viral par-
ticles by infected host cells should induce immune re-
sponses similar to live-attenuated immunodeficiency vi-
ruses, finally resulting in the clearance of the infected cells
and potentially protection from challenge. In contrast to
most vector vaccines based on heterologous viruses or bac-
teria, the SCIV do not express any heterologous genes to
which the host could raise an immune response or which
might modulate the immune response.
Results
Design of single-cycle immunodeficiency viruses
Several mutations and deletions were introduced into
the genome of SIV to generate a SCIV expression plas-
mid, designated SX2frxn, encoding a virus that can
undergo only one round of replication (Fig. 1A). The
primer binding site of SIV was mutated to a sequence
designated X2, which avoids complementarity to known
cellular tRNAs (Lund et al., 1997). The resulting defect
in reverse transcription can be rescued by providing an
artificial tRNA (X2-Lys3, Fig. 1B) complementary to the
mutated primer binding site during virus production as
previously described (Hansen et al., 2001). Since the
artificial primer is not present in infected target cells,
these cannot produce infectious virus. The vif gene was
also deleted (Fig. 1A). Vif, which is required for virus
replication in primary cells (Gabuzda et al., 1992), coun-
teracts a cellular factor inhibiting production of infec-
tious virus particles (Sheehey et al., 2002). In some cell
lines, such as 293T cells, the antiviral factor is not ex-
pressed, allowing the production of infectious viral par-
ticles in the absence of vif. Infection of primary cells with
these vif-deficient SCIVs should lead to production of
SIV particles that are noninfectious due to the vif defi-
ciency and the primer complementation strategy. In ad-
dition to these two approaches limiting virus replication
to a single cycle the accessory genes vpr, vpx, and nef
were also deleted to further attenuate the SCIV, to pre-
vent down regulation of MHC-I by Nef (Piguet et al.,
1999), and to avoid Vpr-induced cell cycle arrest
(Planelles et al., 1996) (Fig. 1).
Fig. 1. Map of the SCIV expression plasmid, SX2frxn (A), and predicted structure of the complementing tRNA, X2-Lys3 (B). Open reading frames and
relevant regulatory elements are shown as open boxes. Accessory genes inactivated by deletions are shaded. The sequence of the mutated primer binding site
is given along with the wild-type sequence (wt). (B) The predicted secondary structure of the complementing X2-Lys3 tRNA is shown with mutated bases
marked by boxes. Arrows indicate the region of complementarity between the 18 bases of the mutated PBS and the artificial tRNA.
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Characterization of single-cycle immunodeficiency viruses
in cell culture
To produce SCIV particles, 293T cells were cotrans-
fected with SX2frxn and X2-Lys3, the expression plasmid
for the complementing tRNA. The viral titer in the super-
natant of transfected cells on an indicator cell line express-
ing -galactosidase under the control of the HIV-1 LTR was
approximately 1  104 infectious units/ml (Table 1). Omit-
ting X2-Lys3 from the transfection reduced the titer to
background levels (Table 1). The titer could be increased to
1.5  106/ml by cotransfection of SIV-X2frxn and X2-
Lys3 with an expression plasmid for the G-protein
(pVSV-G) of vesicular stomatitis virus (Table 1). The titer
is approximately 10-fold higher than the titers obtained after
transfection of a replication competent, nef-deletion mutant
of SIV expressing the gene for the green fluorescent protein
in place of nef (SIV-GFP, Table 1).
SCIV particles produced by transfection of 293T cells
were further characterized by Western blot analysis (Fig. 2).
Particle-associated Gag and Env proteins could be detected
independent of cotransfection of the complementing X2-
Lys3 tRNA expression plasmid. The supernatants from the
transfected producer cells were used to infect 293A target
cells. Particle-associated Gag and Env proteins could only
be detected in the supernatant of target cells infected with
the supernatant of producer cells cotransfected with
SX2frxn and X2-Lys3. In the absence of X2-Lys3, Gag
and Env expression was not observed in the infected target
cells.
The replication properties of SCIV were analyzed on
CEM  SEAP indicator cells, which secrete alkaline phos-
phatase after infection with SIV (Means et al., 1997). CEM
 SEAP cells were incubated with the supernatant of 293T
cells transfected with SX2frxn and pVSV-G in the pres-
ence or absence of X2-Lys3. High SEAP activities in CEM
 SEAP cultures 2 and 4 days after incubation with
SX2frxn in the presence of X2-Lys3, but not in its ab-
sence, indicated efficient infection by SCIV particles (Fig.
3). Extensive syncytia formation in the SCIV-infected cul-
tures indicated production of fusion competent Env proteins
(data not shown). Outgrowth of potential replication com-
petent recombinants of SCIV could not be followed directly
in this culture due to cell death induced by the high-dose
SCIV infection. To analyze whether replication competent
virus would be produced by the SCIV-infected cells, fresh
CEM  SEAP cells were incubated with the supernatant of
Table 1
SCIV titer
Transfected plasmids Titer (LFU/ml)
Expt. 1 Expt. 2
SX2frxn 1.2 103 0.5  103
SX2frxn  X2Lys3 1.1  104 9.8  103
SX2frxn  pVSV-G 2.1  103 1.7  103
SX2frxn  X2Lys3  pVSV-G 1.5  106 2.0  106
SIV-GFP 1.3  105 1.3  105
None 1.3  103 1.4  103
Note. 293T cells were transfected with the indicated plasmids. The titer
in the supernatant of transfected cells was determined on S-Magi cells.
LFU: LacZ forming units. SX2frxn and X2-Lys3 are described in Fig. 1.
pVSV-G: expression plasmid for the G protein of vesicular stomatitis
virus; SIV-GFP: nef deletion mutant of SIVmac239 expressing GFP in
place of nef.
Fig. 2. Western blot analysis of particle production by transfected producer cells and infected target cells. 293T cells were transfected with the indicated
plasmids. The supernatant of transfected producer cells was used to infected 293A target cells. Viral particles were prepared from the supernatant of
transfected producer cells and infected target cells and analyzed by Western blot with a serum from an SIV-infected monkey.
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the infected cells. SEAP activity induced by the supernatant
of cells infected with SX2frxn in the presence of X2-Lys3
was only slightly elevated early after exposure and returned
to baseline levels thereafter (Fig. 3). In contrast, the super-
natant of a CEM  SEAP culture infected with the repli-
cation competent SIV-GFP induced a rapid increase in
SEAP activity and extensive cell death was observed.
Expression and immunogenicity of single-cycle
immunodeficiency viruses in rhesus monkeys
Injection of SCIVs into rhesus monkeys should lead to
infection of host cells turning them into producer cells for
noninfectious SIV particles. Given that the half-life of in-
jected viral particles is in the order of minutes (Zhang et al.,
1999) and since free RNA is rapidly eliminated from
plasma, persistent detection of SIV RNA in the plasma
should indicate in vivo production of SIV particles. Two
rhesus monkeys were intravenously inoculated with 107
infectious units of SCIV generated by cotransfection of
SX2frxn with X2-Lys3 and the VSV-G expression plas-
mid. The same dose was subcutaneously administered to an
additional two monkeys. After 4 and 8 weeks, all monkeys
were boosted with the same dose and by the same route as
for the first inoculation. SIV RNA peaked 2 to 4 days after
the first intravenous injection and remained detectable for 2
weeks (Table 2). However, no SIV RNA could be detected
after the second intravenous injection. In the subcutane-
ously injected group, SIV RNA could only be detected at
one time point in one of the two monkeys. SIV DNA could
not be detected by PCR in the SIV RNA-positive samples
(data not shown), excluding contamination of the plasma
samples with plasmid DNA present in the SCIV inoculum.
Western blot analyses revealed the induction of SIV-
specific antibodies 4 to 8 weeks after the first SCIV injec-
tion in animals 15 i.v., 22 s.c., and 36 s.c. (Fig. 4). The first
booster immunization at week 4 seemed to increase anti-
body levels to CA in these monkeys. Antibodies to Env
were only detectable by Western blot analysis in monkey 36
s.c. This animal also had the highest antibody titers to Env
in a more sensitive ELISA assay (Table 3), which also
revealed low levels of antibodies to Env in all animals 10
weeks after the first immunization. At this time point, an-
tibodies to p27 CA could also be detected by ELISA in all
animals (Table 3). Antibody titers to Env increased in all
animals between the 6- and 10-week time point, indicating
a booster effect of the third immunization at week 8. Three
of the four animals also showed an increase in antibody
titers to p27 CA during this time period. Nineteen weeks
after the first immunization antibodies to Env and p27 CA
remained detectable, but titers are approximately two orders
of magnitude lower than those obtained after infection with
Fig. 3. Assay for the detection of replication competent SCIVs. CEMx-
SEAP cells were infected with supernatants of 293T cells transfected with
the indicated plasmids and pVSV-G in case of SX2frxn transfections.
Four days after the first infection (1st) the supernatants of the infected cells
were incubated with fresh CEMxSEAP cells (2nd). RLU: relative light
units in the supernatant of infected cells.
Table 2
SIV RNA levels in plasma after SCIV injection
Animal RNA copies/ml at indicated days after 1st inoculation
2 4 7 14 28 30 32 35 42
15 i.v. 2300 2400 1600 510 40 40 40 40 40
16 i.v. 15,000 14,000 4800 150 40 40 40 40 40
22 s.c. 40 40 40 40 40 40 40 40 40
36 s.c. 40 1000 40 40 40 40 40 40 40
Note. Viral RNA levels in the plasma of monkeys injected with SCIVs on day 0 and 28. The two digit numbers are animal designations followed by an
abbreviation of the route of SCIV injection: i.v.: intravenous; s.c.: subcutaneous.
Fig. 4. Western blot analysis for anti-SIV antibodies. Sera were collected
at the indicated weeks after the first SCIV injection and used at a 1:50
dilution. Animal designations are as in Table 2. “” : positive control
serum from an SIV-infected macaque.
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a nef deletion mutants of SIV (Gundlach et al., 1997).
Determination of neutralizing antibody titers revealed that
the antibodies to SIV Env detected by ELISA did not lead
to neutralization (Fig. 5A). However, high neutralizing ac-
tivity against VSV-G was observed in all animals 10 and 12
weeks after the first immunization (Fig. 5B).
SIV Gag-specific T helper cell proliferation could also be
detected repeatedly in three of the four animals starting after
the first boost (Fig. 6). All attempts to isolate replication
competent virus by a sensitive coculture technique failed
(data not shown).
Challenge of monkeys immunized with single-cycle
immunodeficiency viruses
Twelve weeks after the last booster immunization the
four SCIV-immunized (2 s.c., 2 i.v.) monkeys were challenged
intravenously with 25 MID50 of pathogenic SIVmac239. As a
control, three naive monkeys were also inoculated with the
same dose. Two weeks after challenge, mean peak plasma viral
RNA levels were found to be approximately 17-fold lower in
the immunized animals than in the control group (Fig. 7).
This difference was statistically significant (P  0,004).
However, 24 weeks following SIVmac239 challenge,
steady-state virus loads failed to reveal differences between
the SCIV-immunized animals and controls.
Discussion
The in vitro characterization of SCIVs demonstrates that
they could be produced by transfection of the vif-indepen-
dent 293T producer cell line at titers of 106 infectious
units/ml. In the absence of the complementing tRNA titers
were reduced to background levels, indicating the depen-
dency on the complementing tRNA. SCIV-infected target
cells produced viral particles containing Gag and fusion-
competent Env proteins. As expected, the particles pro-
duced by the infected target cells were not able to replicate
in the vif-dependent CEM  SEAP cells. The replication
deficiency was not only due to the deletion in vif, since
repeated attempts to propagate vif-expressing SIV, only
impaired for replication by the mutated primer binding site,
were not successful (data not shown). Since both the defect
in the primer binding site and the vif defect are comple-
mented during SCIV production with genes heterologous to
SIV emergence of replication competent SCIVs by homol-
Table 3
SIV antibody titers after immunization with SCIV
Animal Antibody titer to
gp130 at wpi p27 CA at wpi
6 10 19 6 10 19
15 i.v. 100 100 100 100 200 100
16 i.v. 100 200 100 100 100 100
22 s.c. 100 200 100 200 200 200
36 s.c. 800 1600 200 100 400 100
Note. Antibody titers in four monkeys at indicated weeks after first
injection (wpi) of SCIVs. Animal designations are as in Table 2.
Fig. 5. Neutralizing antibody response to SIV-Env and VSV-G. The titer of
SIV-based vectors pseudotyped with SIV-Env (A) or VSV-G (B) was
determined on S-Magi cells in the presence of a 1/10 dilution (A) or a 1/50
dilution (B) of plasma from the immunized animals at the indicated weeks
(wpi) prior to or after the first immunization. GFU: green fluorescence
forming units.
Fig. 6. Lymphoproliferative response to SIV Gag. PBMCs from the im-
munized monkeys at the indicated weeks after the first SCIV injection
(wpi) were stimulated with SIV Gag-VLP and proliferation was deter-
mined by 3[H]thymidine incorporation. The stimulation index was calcu-
lated by dividing the mean count of the antigen-containing cultures through
that of cultures lacking the antigen. Stimulation indices 5 were consid-
ered positive. Animal designations are as in Table 2.
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ogous, recombination seems unlikely. Monkeys inoculated
with vif deletion mutants of SIV remained virus isolation
negative (Desrosiers et al., 1998). Low levels of anti-SIV
antibodies in these monkeys, but not in monkeys injected
with heat-inactivated SIV, might suggest low-level replica-
tion of the vif deletion mutant (Desrosiers et al., 1998).
Alternatively, production of viral particles by cells infected
with viruses from the inoculum could have been responsible
for the observed immune response. Combining the deletion
in vif with the mutation of the primer binding site should
reliably block replication of SCIVs in vivo. This is an
important safety aspect, in which SCIVs differ from live-
attenuated SIV vaccines.
Intravenous administration of SCIVs into rhesus mon-
keys generated peak plasma RNA levels in the range of 103
to 104 copies/ml and SIV RNA levels in the plasma were
detectable for 2 weeks, demonstrating the in vivo produc-
tion of SIV particles. The absence of detectable SIV RNA
after the second intravenous SCIV injection is evidence that
host immune responses induced by the first SCIV adminis-
tration were capable of removing virus particle from circu-
lation and/or eliminate infected cells. Antibodies to struc-
tural SIV antigens as well as SIV Gag-specific T helper cell
proliferative responses were detected in the immunized
monkeys. However, immunization with SCIV did not lead
to detectable amounts of neutralizing antibodies to SIV-
Env. In contrast, plasma from SCIV-immunized monkeys
efficiently inhibited the infectivity of a VSV-G pseudotyped
vector. Since the injected SCIV particles were also
pseudotyped with VSV-G, anti-VSV-G antibodies probably
play a role in prevention of infection of rhesus monkey
target cells during booster immunization, thereby reducing
the immunostimulatory capacity of SCIV booster injections
to a conventional protein boost. Replacement of VSV-G by
other viral envelope proteins might enhance the efficiency
of SCIV booster immunizations.
Although SCIV immunization significantly reduced peak
viral RNA levels 2 weeks after intravenous SIV challenge,
this result must be interpreted with caution due to the low
number of animals used in this study. The schedule of SCIV
administration used in this proof of principle study did not
seem to induce sufficient immunity to provide long-term
benefits. In contrast to effective live-attenuated SIV vac-
cines, such as nef deletion mutants, there seem to be two
main differences. The peak viral RNA levels reached by
effective live-attenuated SIV vaccines during primary infec-
tion is on the order of 105 to 106 copies/ml (Desrosiers et al.,
1998; Gundlach et al., 1997), while the RNA levels in
monkeys intravenously injected with SCIVs are approxi-
mately 10- to 100-fold lower. The host cells producing SIV
particles probably also differ from the cells infected with
live-attenuated immunodeficiency viruses, since the VSV-G
used for pseudotyping of the SCIVs should expand their cell
tropism. Vaccination with concentrated SCIVs at higher
doses might lead to similar levels of antigen expression as
observed after vaccination with nef deletion mutants of SIV.
Since the efficacy of live-attenuated SIV vaccines seems to
correlate with their replicative capacity in monkeys (John-
son et al., 1999; Lohman et al., 1994), one could then
determine whether expression levels itself are sufficient for
induction of protective immune responses or whether rep-
lication of the vaccine virus is required. Other immunization
schedules such as longer intervals between injections,
prime-boost regimens, and/or mucosal administrations also
remain to be explored.
Our results further demonstrate that with the SCIV ap-
proach it is possible to uncouple viral expression levels
from the replicative capacity. This should facilitate further
studies on the effect of viral genes, such as nef, in the
context of a proviral genome on antiviral immune responses
independent of their effect on virus replication.
Fig. 7. Viral RNA load in plasma of SCIV-immunized monkeys (A) and control animals (B) after challenge with SIVmac239. Monkeys were inoculated
intravenously with 25 MID50 of SIVmac239 12 weeks after the last SCIV immunization. Animal designations are as in Table 2. Control monkeys in (B) are
identified by a five-digit number.
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Material and methods
Plasmid constructions
A 6.6-kb BamH1-Xma1 fragment of SIVmac239 span-
ning the 3 half of gag to the 3 end of env with deletion in
vif, vpr, and vpx (described in Gibbs et al., 1994) was cloned
into a 6.2-kb Xma1-BamH1 fragment of SIV-GFP-X2 (Han-
sen et al., 2001) comprising the plasmid back bone, both
ends of the viral genome, a mutated primer binding site
designated X2, and a deletion in nef and the 3U3 region
(described in Gundlach et al., 1997), resulting in SX2frxn.
The tRNA expression plasmid X2-Lys3 (Hansen et al.,
2001) and the VSV-G expression plasmid pVSV-G
(pHIT-G in Fouchier et al., 1997) have been previously
described. SIV-GFP (Wagner et al., 2000) is a nef deletion
mutant of SIV containing the GFP gene in place of nef,
similar in design to a SIV nef deletion mutant expressing
interleukin-2 (Gundlach et al., 1997), and was used as a
replication competent control virus. The ViGSB vector
was constructed by deletion of a SpeI-BspE1 fragment from
ViGBH (Schnell et al., 2000).
Production and titration of SCIV
The 293T (293ts/A1609) (DuBridge et al., 1987), 293A
(strongly adherent subclone of 293, Quantum Biotechnolo-
gies, Montreal, Canada), and S-MAGI cells (Chackerian et
al., 1995) were maintained in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal calf serum (FCS),
penicillin, streptomycin, and glutamine. The 293T cells
were transfected with the calcium phosphate coprecipitation
method as described (Soneoka et al., 1995). Five micro-
grams of SX2frxn, X2-Lys3, and pVSV-G were each used
for transfection of 25-cm2 flasks. Two days after transfec-
tion, the supernatant of the transfected cells was passed
through a 0.45-m filter and stored in aliquots at 80°C.
For titration, S-Magi indicator cell lines, containing the
-galactosidase gene downstream of the HIV-1 LTR, were
seeded at a density of 2.5  104 cells per well of a 24-well
plate. One day later, 200 l of serial dilutions of the super-
natants of the transfected cells was incubated with the S-
Magi cells for 3 h prior to addition of fresh medium. Two
days later, S-MAGI cells were stained with 5-bromo-4-
chloro-3-indolyl--D-galactopyranoside (X-Gal) essentially
as described (Chackerian et al., 1995). The titer of the
SCIVs was calculated from the number of stained cells per
well and was expressed as lacZ-forming units (LFU)/ml.
Western blot analysis of viral particles
The supernatants of 293T cells transfected in parallel
with the indicated plasmids as described above were used to
infect 293A cells. The supernatant of the infected cells was
harvested 2 days after infection and filtered through a
0.45-m filter. Five milliliters of the filtered supernatants of
transfected 293T cells and SCIV-infected 293A cells were
pelleted through a 20% sucrose cushion by ultracentrifuga-
tion. Pellets were resuspended in 50 l of protein loading
buffer and 15 l was loaded on a 10% polyacrylamide gel
to separate particle associated proteins. After blotting onto
Immobilon-P membranes (Millipore, Bedford, MA, USA)
according to standard procedures, SIV antigens were de-
tected with a 1:1000 dilution of the plasma of an SIV-
infected rhesus monkey (S1604) and a horseradish peroxi-
dase conjugated, antihuman IgG secondary antibody (Dako,
Glostrup, Denmark) followed by DAB staining.
Detection of replication competent viruses
One milliliter of SCIV generated by transfection of 293T
cells with SX2frxn, pVSV-G, and X2-Lys3 with a titer of
1.5  106 LFU/ml was used to infect 106 CEM  SEAP
cells, which express the secreted alkaline phosphatase
(SEAP) gene under the control of the SIV-LTR (Means et
al., 1997). As controls 1 ml supernatant of 293T cells
transfected with SX2frxn and VSV-G in the absence of
X2-Lys3 or SIV-GFP (titer: 2  105 LFU/ml) was also
used. After incubation for 3 h, cells were washed twice in
PBS and cultured in 25-cm2 flasks in 5 ml fresh RMPI
medium containing 10% FCS. Two days later cells were
split one to five and cultured for another 2 days in 5 ml
medium. The supernatant of the culture was harvested 4
days after infection and used to infected fresh CEM 
SEAP cells as described above. The cultures were main-
tained for 1 month with splitting twice a week. Supernatants
collected at various time points were analyzed for SEAP
activity using the Phospha-Light kit as described by the
manufacturer (Tropix, Bedford, MA, USA).
Immunization and challenge of rhesus monkeys
Animals were housed at the German Primate Center in
Go¨ttingen. Handling of the monkeys and collection of spec-
imens were performed according to institutional guidelines
as described previously (Stahl-Hennig et al., 1990). Two
rhesus monkeys of Indian origin (seronegative for SIV,
D-type retroviruses, and STLV-1) were injected intrave-
nously and two monkeys were injected subcutaneously with
10 ml of SCIVs three times in monthly intervals. For sub-
cutaneous injections, the 10 ml total volume was injected at
three different sites. The SCIVs were generated by transient
cotransfection of 293T cells in 182-cm2 tissue culture flasks
with 40 g each of SX2frxn, X2-Lys3, and VSV-G. One
day after transfection, the FCS-containing medium was re-
placed by serum-free AIM-V medium (Gibco-Invitrogen
Corp., Karlsruhe, Germany) and supernatants were col-
lected and filtered 24 h later as described above. The titer of
the SCIV in the supernatant of the transfected cells was
adjusted to 106 LFU/ml, corresponding to 260 ng/ml reverse
transcriptase as determined by the RT easy kit (Roche
Diagnostics, Mannheim, Germany).
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All immunized animals were challenged intravenously
12 weeks after the last booster immunization along with
three control monkeys with 25 median monkey infectious
doses (MID50) of cell-free pathogenic SIVmac239.
Viral load and antiviral immune responses
Quantitative RNA PCR was used to determine the virus
load in plasma as previously described (ten Haaft et al.,
1998). To exclude contamination of the plasma samples
with plasmid DNA from the SCIV inoculum, the PCR was
also performed with the same primers in the absence of
reverse transcriptase.
Antibodies to the SIV polypeptides Env and Gag were
determined by ELISA as described (Stahl-Hennig et al.,
1992). Instead of whole-lysed SIV antigen recombinant SIV
gp130 and SIV p27 kindly provided by Program EVA were
used. SIV antigen for the Western blot was prepared by
passage of SIV-GFP in CEM  174 cells. The supernatant
of infected cells was pelleted through a 20% sucrose cush-
ion and the viral proteins from the pellet were separated by
SDS–PAGE. The gel was blotted onto immobilon-P mem-
branes which were then cut in strips. Plasma from the
immunized monkeys was used in a 1:50 dilution for incu-
bation with the Western blot strips. Bound antibodies were
detected by a horseradish peroxidase conjugated secondary
antibody directed against human IgG (Dako). As a positive
control, plasma from a SIV-infected rhesus monkey
(S1604) was used in a 1:1000 dilution.
For the detection of neutralizing antibodies, the titer of
lentiviral vectors containing SIV-Env or VSV-G for entry
into cells was determined in the presence or absence of
different dilutions of monkey plasma. The vector particles
were produced by transient cotransfection of 293T cells
with the SIV vector construct, pViGSB, transferring GFP,
a SIV Gag-pol expressing plasmid (Sgp2) (Schnell et al.,
2000), and pVSV-G or an SIV-Env expression plasmid
(pS-Env) (Schnell et al., 2000), respectively. Sixty micro-
liters of vector containing supernatants with a titer of ap-
proximately 104 to 105 infectious units were mixed with 30
l of different dilutions of plasma samples collected from
immunized animals at different time points prior to and post
immunization. The mixture was incubated at 37°C for 30
min, and 30 l was added in triplicates on S-MAGI cells
platted into 96-well plates at a density of 1  104 cells/well
1 day prior to the infection. Three hours after infection, cells
were fed with fresh 10% DMEM medium and the viral titers
were determined 2 days later by calculating green fluores-
cence protein forming units (GFU)/ml supernatant from the
number GFP positive cells per well.
For the T cell proliferation assay, PBMCs were stimu-
lated with 0.25 g purified baculovirus-derived SIV Gag-
VLP (Notka et al., 1999) for 7 days and [3H]thymidine
incorporation was measured after a 6-h incubation period
(Hoch et al., 1995). The stimulation index was calculated
from the mean counts of triplicate wells by dividing the
mean counts of antigen-containing cultures through the
mean counts of cultures without antigen. Stimulation indi-
ces over five were considered positive.
Statistical analysis
Viral RNA levels 2 weeks after challenge were com-
pared by the two-tailed t-test using the logarithmically
transformed RNA copy numbers of each animal with the
SigmaStat (version 2.03, SPSS Inc., San Rafael, CA, USA)
statistical software package.
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